Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents

BACKGROUND: Sofosbuvir is the keystone of direct antiviral agents for the chronic hepatitis C (CHC). The safety of sofosbuvir in patients with stage 4–5 chronic kidney disease (CKD) needs further observation in real world. CASE PRESENTATION: Thirty-three patients with stage 5 CKD and hepatitis C vir...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Taotao, Wang, Jiuping, Li, Juan, Fu, Shan, Chen, Yi, Hu, Chunhua, Zhang, Rou, Tian, Zhen, Zhao, Fahui, Dong, Jun, Liu, Jinfeng, Yang, Yuan, Chen, Tianyan, Zhao, Yingren, He, Yingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588848/
https://www.ncbi.nlm.nih.gov/pubmed/31226947
http://dx.doi.org/10.1186/s12879-019-4117-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588848/
https://www.ncbi.nlm.nih.gov/pubmed/31226947
http://dx.doi.org/10.1186/s12879-019-4117-x

Ejemplares similares